Clinical trials: Neoplasms Recurrence
Ewing's Sarcoma, Osteosarcoma
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
The best treatment for recurrent cancers or those that do not respond to therapies is not known. Typically, patients with these cancers receive a combination of cancer drugs (chemotherapy), surgery, or radiation therapy.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor
- Trial name
- Aflac ST0901 (NCT01331135)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Hepatoblastoma
A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
Hepatoblastoma is the most common malignant liver tumor in infants and preschool children, comprising 65% of pediatric liver malignancies in those under 15, with its incidence on the rise in recent years [1].
- Trial name
- NCT07300449
- Testing
- Very low-risk group, Low-risk group, Intermediate-risk group
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
This phase II trial is studying how well tipifarnib works in treating young patients with recurrent or progressive high-grade glioma, medulloblastoma, primitive neuroectodermal tumor, or brain stem glioma.
- Conditions
- Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
- Trial name
- NCT00070525
- Testing
- tipifarnib
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00005576
- Testing
- monoclonal antibody Ch14.18, isotretinoin, aldesleukin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia (AML)
Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML
1. To evaluate whether stem cell transplantation from a matched sibling donor is equivalent to a matched unrelated donor in in a second complete remission of acute myeloid leukemia (AML). 2.
- Trial name
- NCT00606723
- Testing
- Hematopoietic stem cells from bone marrow or peripheral blood
- Where
- 24 sites in Austria, Czechia and 1 more
- Volunteers
- 154 people
- Sponsor
- Hannover Medical School
T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
This is a multi-centers, single-arm, open label, Phase 2 clinical trial to evaluate the efficacy and safety of CD7 CAR T cells in subjects with relapsed or refractory T-cell leukemia/lymphoma. Seventy subjects will be enrolled.
- Conditions
- T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence
- Trial name
- NCT04689659
- Testing
- chimeric antigen receptor T cell treatment
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Beijing Boren Hospital
Leukemia
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase I trial to study the effectiveness of augmerosen plus fludarabine and cytarabine in treating patients who have refractory or relapsed acute myeloid leukemia or acute lymphoblastic leukemia.
- Trial name
- NCT00004862
- Testing
- filgrastim, oblimersen sodium, cytarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Pediatric ALL, Relapsed Pediatric ALL
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred).
- Conditions
- Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
- Trial name
- NCT00439296
- Testing
- ABT-751, Dexamethasone, PEG-asparaginase
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Breast Cancer Surgery, Benign Breast Tumors
Analysis of Recurrence of Intraductal Papilloma Treated With Vacuum-assisted Rotary Excision
To study the postoperative recurrence of intraductal papillomas (IDP) treated with ultrasound-guided vacuum-assisted excision (VAE), and to investigate the effect of different lesion characteristics on recurrence.
- Trial name
- IDP (NCT06970561)
- Testing
- enlarged resection
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Wuhan Children's Hospital
Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004169
- Testing
- carboplatin, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Northwestern University
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Bone Metastases, Castrate-resistant Prostate Cancer
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
This study is being done to help researchers understand more about prostate cancer that has spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to better understand the effect of an…
- Conditions
- Bone Metastases, Castrate-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01599793
- Testing
- cabozantinib, laboratory biomarker analysis, magnetic resonance imaging
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Gastric Cancer
Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk
The Systemic Oxidative Stress Score (SOSS) , a comprehensive score reflecting the oxidative stress conditions in the microenvironment, can independently and effectively predict tumor burden and long-term prognosis in GC patients.
- Trial name
- NCT06337279
- Where
- China
- Volunteers
- 3,820 people
- Sponsor
- Fujian Medical University
Bone Cyst Aneurysmal, Pathological Fracture
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
The efficacy of traditional therapeutic approaches for aneurysmal bone cysts (ABC), such as surgery, embolization, sclerotherapy and radiotherapy, are often compromised for lesions in axial skeletons and adolescents complicated…
- Conditions
- Bone Cyst Aneurysmal, Pathological Fracture, Recurrent Disease, Refractory Tumor
- Trial name
- Deno-ABC (NCT03415477)
- Testing
- Denosumab (Xgeva)
- Volunteers
- 6 people
- Sponsor
- Peking University People's Hospital
Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that…
- Conditions
- Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma
- Trial name
- NCT06620302
- Testing
- Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan
- Where
- 21 sites in United States
- Volunteers
- 81 people
- Sponsor
- Children's Oncology Group
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia").
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- SAGAN (NCT01853631)
- Testing
- Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Baylor College of Medicine
Diffuse Large B-cell Lymphoma
Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma
The investigators perform a retrospective microarray gene expression profiling study of FFPE from a cohort of DLBCL patients with whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay.
- Trial name
- NCT01606605
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Samsung Medical Center
Solid Tumor
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Most pediatric patients with solid tumors respond to initial high-dose, intensive therapy and complete treatment in remission. High-risk patients however, frequently have recurrent disease which is then treated with ad hoc…
- Trial name
- Metronomic (NCT02446431)
- Testing
- Bevacizumab, Cyclophosphamide, Valproic Acid
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Miller Children's & Women's Hospital Long Beach
Osteosarcoma, Osteosarcoma in Children
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
- Conditions
- Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Osteosarcoma Metastatic
- Trial name
- NCT04803877
- Testing
- Regorafenib 40 MG, Regorafenib 20MG, Nivolumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration